APA (7th ed.) Citation

Dinh, J. C., Boone, E. C., Staggs, V. S., Pearce, R. E., Wang, W. Y., Gaedigk, R., . . . Gaedigk, A. (2022). The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity. Clinical pharmacology and therapeutics, 111(3), 646. https://doi.org/10.1002/cpt.2469

Chicago Style (17th ed.) Citation

Dinh, Jean C., Erin C. Boone, Vincent S. Staggs, Robin E. Pearce, Wendy Y. Wang, Roger Gaedigk, James Steven Leeder, and Andrea Gaedigk. "The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity." Clinical Pharmacology and Therapeutics 111, no. 3 (2022): 646. https://doi.org/10.1002/cpt.2469.

MLA (9th ed.) Citation

Dinh, Jean C., et al. "The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity." Clinical Pharmacology and Therapeutics, vol. 111, no. 3, 2022, p. 646, https://doi.org/10.1002/cpt.2469.